



Press Release

Thursday, October 20, 2011



Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR BUPIVACAINE HYDROCHLORIDE INJECTION, USP

- **Approval for 2 ANDAs**

October 20, 2011, Bangalore: Strides Arcolab Limited (Strides) today announced that it has received 2 ANDA approvals from US FDA for Bupivacaine Hydrochloride Injection, USP, a general anaesthetic for the following strengths:


- Bupivacaine Hydrochloride Injection, USP, 0.25%, 0.5% and 0.75% packaged in 10 mL and 30 mL Single-dose Vials (Preservative Free).
- Bupivacaine Hydrochloride Injection, USP, 0.25% (2.5 mg/ mL) and 0.5% (5 mg/ mL) each packaged in 50 mL Multiple-dose Vials.

According to IMS, the 2011 U.S. market for Injectable Bupivacaine Hydrochloride approximates to USD 29 million. The product is expected to be launched shortly.

Bupivacaine is the thirteenth product approved under the Sagent - Strides partnership. Strides is developing and supplying more than 25 injectable products for the USA market which will be marketed by Sagent

About Bupivacaine Hydrochloride Injection

Bupivacaine hydrochloride is indicated for the production of local or regional anaesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anaesthesia.



About Agila Specialties

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 70 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

About Strides Arcolab Limited

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company's website at www.stridesarco.com.

For further information, please contact:

<u>Strides</u>	<u>PR Consultancy</u>
Mr. V.S. Iyer, CEO - Agila +91 80 6784 0111	Corporate Voice Weber Shandwick Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in
Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)	Hiba Kunil +91 98807 26372 hiba@corvoshandwick.co.in

